Business Description
Arcturus Therapeutics Holdings Inc
NAICS : 325414
SIC : 2834
Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.88 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.09 | |||||
| Beneish M-Score | 0.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -33 | |||||
| 3-Year EBITDA Growth Rate | -53.8 | |||||
| 3-Year EPS without NRI Growth Rate | -53 | |||||
| 3-Year FCF Growth Rate | -33.5 | |||||
| 3-Year Book Growth Rate | 89.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.51 | |||||
| 9-Day RSI | 50.41 | |||||
| 14-Day RSI | 48.11 | |||||
| 6-1 Month Momentum % | -47.92 | |||||
| 12-1 Month Momentum % | -70.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.14 | |||||
| Quick Ratio | 3.14 | |||||
| Cash Ratio | 3.06 | |||||
| Days Sales Outstanding | 24.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -404.1 | |||||
| Net Margin % | -407.91 | |||||
| ROE % | -72.04 | |||||
| ROA % | -42.32 | |||||
| ROIC % | -185.65 | |||||
| ROC (Joel Greenblatt) % | -923.51 | |||||
| ROCE % | -55.44 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.64 | |||||
| PB Ratio | 2.29 | |||||
| Price-to-Tangible-Book | 2.29 | |||||
| EV-to-EBIT | -1.28 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Revenue | 5.15 | |||||
| EV-to-Forward-Revenue | 1.34 | |||||
| EV-to-FCF | -1.4 | |||||
| Price-to-Net-Current-Asset-Value | 3.13 | |||||
| Price-to-Net-Cash | 3.34 | |||||
| Earnings Yield (Greenblatt) % | -78.13 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARCT
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 40.568 | ||
| EPS (TTM) ($) | -6.28 | ||
| Beta | 2.63 | ||
| Volatility % | 49.91 | ||
| 14-Day RSI | 48.11 | ||
| 14-Day ATR ($) | 1.308952 | ||
| 20-Day SMA ($) | 14.837 | ||
| 12-1 Month Momentum % | -70.62 | ||
| 52-Week Range ($) | 11.7 - 48.75 | ||
| Shares Outstanding (Mil) | 26.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcturus Therapeutics Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcturus Therapeutics Holdings Inc Analysis
Share your researchHeadlines
See More
No news.